Business
Magenta Therapeutics to Host Business Update Conference Call
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates. The call will also feature a discussion of current stem cell transplant practices by a transplant key opinion leader.\n\n\nTo access the call, please reference the dial-in details below. A playback of the call will be available on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations for 90 days following the call.\n\n\nConference ID number: 9594495\nU.S./CANADA: (866) 688-5232; (409) 217-8328\nUK (London): 08000288438\nSwitzerland: 0225803283\nAustralia: 1800005989\n\n\nAbout Magenta Therapeutics\nMagenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.\n\n\nMagenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.\n\n\nFollow Magenta on Twitter: @magentatx.\n\n\nForward-Looking Statement\nThis press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption “Risk Factors” in Magenta’s Registration Statement on Form S-1, as updated by Magenta’s most recent Quarterly ...